Thursday, November 24, 2011
Paul Lucas, President and CEO of GlaxoSmithKline Inc., is pleased to announce the appointment of Glenn Crater to Country Medical Director, responsible for leading the company’s Canadian medical division activities.
Since joining GlaxoSmithKline’s U.S. operations in 2004, Dr. Crater has held increasingly responsible positions within the business. Most recently, Dr. Crater served as Director, Clinical Development, within the Respiratory Medicine Development Center for North America.
Prior to his recent move to Canada, Dr. Crater also practiced weekly at a free clinic for difficult-to-treat respiratory patients in North Carolina.
With over 18 years of medical experience, Dr. Crater will be a great asset to GlaxoSmithKline’s Executive Team in Canada, bringing a wealth of knowledge in the areas of clinical development planning, collaborative research trials, health outcomes and economic research, as well as tremendous leadership through interfaces with healthcare practitioners, patient groups, health ministries and regulatory authorities.
Dr. Crater holds a Bachelor of Science degree from Wake Forest University (North Carolina), Doctor of Medicine from the University of Tennessee and completed his Pulmonary and Critical Care Medicine Fellowship at the University of Florida.
GlaxoSmithKline (GSK) is a leading research-based pharmaceutical company with a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives GSK the purpose to develop innovative medicines, vaccines and healthcare solutions that help millions of people. GSK is consistently recognized as one of the 50 best employers in Canada and is a top 15 investor in Canadian research and development, contributing more than $141 million in 2010 alone. With a proud tradition of charitable and community support, GSK is designated a Caring Company by Imagine Canada.
Discover more at www.gsk.ca.
Back to top